Sermorelin Research for Growth Hormone Deficiency
An evidence-based overview of research examining Sermorelin in the context of growth hormone deficiency. This page synthesizes findings from peer-reviewed literature.
Research Summary
Sermorelin was FDA-approved for pediatric growth hormone deficiency, making it one of few GHRH analogs with established regulatory approval for a defined indication. The Geref International Study demonstrated that 74% of GH-deficient children showed increased growth rate after 6 months of treatment.
The mechanism works by stimulating the pituitary to release endogenous GH, preserving natural pulsatile secretion and feedback systems. This distinguishes it from direct GH replacement and may offer advantages in preserving physiologic GH patterns.
While commercially discontinued in 2008 for business reasons (not safety concerns), the historical approval data established sermorelin's efficacy and safety profile for GH deficiency.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Growth Hormone Deficiency
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Sermorelin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.